Direct Oral Anticoagulants and the Patient-Reported Outcomes: Synthesis and Advances

Research output: Chapter in Book/Report/Conference proceedingEntry for encyclopedia/dictionary

Abstract

Anticoagulation treatment with warfarin has been the gold standard of therapy for patients with atrial fibrillation to prevent stroke and for the treatment and prevention of venous thromboembolism. The development of direct oral anticoagulant agents over the past 10 years has created a shift in traditional management of these conditions. These new agents do not retain the pharmacokinetic and pharmacodynamic challenges associated with warfarin and do not require intensive blood monitoring and dose adjustment. Analyzing patient-reported outcomes incorporating patient satisfaction, adherence, compliance, and health-related quality of life gives prescribers and clinical practitioners an understanding of the patient perspectives of using DOACs. This article will focus on the patient-reported outcomes related to the DOAC treatment.
Original languageEnglish
Title of host publicationEncyclopedia of Pharmacy Practice and Clinical Pharmacy
EditorsZaheer Ud-Din Babar
PublisherElsevier
Pages898-908
Number of pages11
Volume3A
Edition1
ISBN (Electronic)9780128127360
ISBN (Print)9780128127353
Publication statusPublished - 20 Jun 2019

Fingerprint Dive into the research topics of 'Direct Oral Anticoagulants and the Patient-Reported Outcomes: Synthesis and Advances'. Together they form a unique fingerprint.

  • Cite this

    Afzal, S., Hasan, S. S., & Babar, Z-U-D. (2019). Direct Oral Anticoagulants and the Patient-Reported Outcomes: Synthesis and Advances. In Z. U-D. Babar (Ed.), Encyclopedia of Pharmacy Practice and Clinical Pharmacy (1 ed., Vol. 3A, pp. 898-908). Elsevier. https://www.sciencedirect.com/science/article/pii/B978012812735300580X